Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma.
- DOI
- 10.1038/s41408-019-0181-0
- Published
- 2019 Feb 22
- Container
- Blood cancer journal
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41408-019-0181-0,
title = {Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma.},
author = {Ludwig H and Moreau P and Dimopoulos MA and Mateos MV and Kaiser M and Hajek R and Feng S and Cocks K and Buchanan J and Weisel K},
year = {2019},
journal = {Blood cancer journal},
doi = {10.1038/s41408-019-0181-0},
url = {https://doi.org/10.1038/s41408-019-0181-0}
}RIS
TY - JOUR TI - Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. AU - Ludwig H AU - Moreau P AU - Dimopoulos MA AU - Mateos MV AU - Kaiser M AU - Hajek R AU - Feng S AU - Cocks K AU - Buchanan J AU - Weisel K PY - 2019 JO - Blood cancer journal DO - 10.1038/s41408-019-0181-0 UR - https://doi.org/10.1038/s41408-019-0181-0 ER -
APA
H, L., P, M., MA, D., MV, M., M, K., R, H., S, F., K, C., J, B., & K, W. (2019). Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma.. Blood cancer journal. https://doi.org/10.1038/s41408-019-0181-0
Source records
- pubmed · retrieved 2026-09-27T00:43:13.035Z